title: HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions.
abstract: Carbamazepine (CBZ) is frequently used for treating epilepsy, but this drug causes cutaneous adverse drug reactions (cADRs) that may range from mild to severe. It is reported recently that the human leukocyte antigen HLA-B*1502 is associated with Stevens-Johnson syndrome (SJS) induced by CBZ in Han Chinese. We examined HLA class I in 15 Japanese patients who fulfilled the diagnostic criteria for CBZ-induced cADRs (mild in 10 and severe = SJS in 5). HLA-B*1518, HLA-B*5901 and HLA-C*0704 alleles showed higher relative risks (above 10.0) for severe cADRs. The haplotype (HLA-A*2402-B*5901-C*0102) had high relative risk (16.09) for severe cADRs. In patients with severe cADRs, frequencies of HLA-A*1101, HLA-A*3303, HLA-B*1501, HLA-B*4403, HLA-B*5101, HLA-B*5201, HLA-C*0702, and HLA-C*1202 alleles are relatively lower than in the Japanese population. These data may suggest that HLA-B*5901 is one of the candidate markers for CBZ-induced SJS in Japanese.
authors.affiliation: National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan. turandot@wd6.so-net.ne.jp
authors.forename: Hiroko
authors.initials: H
authors.lastname: Ikeda
authors.forename: Yukitoshi
authors.initials: Y
authors.lastname: Takahashi
authors.forename: Etsuko
authors.initials: E
authors.lastname: Yamazaki
authors.forename: Tateki
authors.initials: T
authors.lastname: Fujiwara
authors.forename: Nahoko
authors.initials: N
authors.lastname: Kaniwa
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Saito
authors.forename: Michiko
authors.initials: M
authors.lastname: Aihara
authors.forename: Mariko
authors.initials: M
authors.lastname: Kashiwagi
authors.forename: Masaaki
authors.initials: M
authors.lastname: Muramatsu
mesh_terms: D000293:Adolescent; D000328:Adult; D000483:Alleles; D044466:Asian People / Q000235:genetics*; D002220:Carbamazepine / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D003875:Drug Eruptions / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology*; D004342:Drug Hypersensitivity / Q000235:genetics; D004827:Epilepsy / Q000188:drug therapy* / Q000235:genetics; D005260:Female; D005787:Gene Frequency; D005819:Genetic Markers; D006680:HLA Antigens / Q000235:genetics; D015235:HLA-B Antigens / Q000235:genetics; D059950:HLA-B52 Antigen; D006239:Haplotypes / Q000235:genetics; D015395:Histocompatibility Antigens Class I / Q000235:genetics*; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D010597:Pharmacogenetics; D012307:Risk Factors; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced* / Q000175:diagnosis / Q000235:genetics*
chemical_list: D005819:Genetic Markers; D006680:HLA Antigens; D015235:HLA-B Antigens; C501279:HLA-B*52:01 antigen; D059950:HLA-B52 Antigen; D015395:Histocompatibility Antigens Class I; D002220:Carbamazepine